Premium
The effect of mirtazapine on gastric accommodation, gastric sensitivity to distention, and nutrient tolerance in healthy subjects
Author(s) -
Carbone F.,
Vanuytsel T.,
Tack J.
Publication year - 2017
Publication title -
neurogastroenterology and motility
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.489
H-Index - 105
eISSN - 1365-2982
pISSN - 1350-1925
DOI - 10.1111/nmo.13146
Subject(s) - barostat , mirtazapine , medicine , ingestion , weight loss , meal , stomach , gastroenterology , postprandial , gastric emptying , endocrinology , anesthesia , diabetes mellitus , obesity , antidepressant , hippocampus
Background Disturbances of gastric motor function of functional dyspepsia ( FD ) have been implicated in the pathogenesis of the symptoms, and hence, motility modifying agents are considered for its treatment. Mirtazapine was recently shown to improve symptoms and increase nutrient tolerance in FD patients with weight loss. We aim to evaluate the effect of mirtazapine on gastric sensorimotor function in healthy volunteers ( HV ). Methods Thirty‐one HV underwent an intragastric pressure ( IGP ) and barostat measurements on separate days before and after 3 weeks of placebo or mirtazapine (15 mg). Gastric compliance, sensitivity and accommodation ( GA ) measured by the barostat. GA was quantitated as the difference (delta) in intra‐balloon volume before and after ingestion of 200 mL of a nutrient drink ( ND ). GA measured by IGP was quantitated as the drop of IGP from baseline during the intragastric infusion of ND until maximal satiation. Key Results Mirtazapine significantly increased the bodyweight of subjects (67.8±3.7 to 69.1±3.7 kg; P =.01). Barostat results showed no effect on gastric compliance, sensitivity, and GA . Nutrient tolerance was not affected after treatment (1170±129.4 vs 1104±133.6 kcal; P =.4), and mirtazapine was associated with lower symptom ratings. The IGP drop during meal ingestion was significantly suppressed (area under the curve: −43.3±4.5 mm Hg vs −28.9±3.1 mm Hg; P =.005). Conclusions & Inferences In HV s, the occurrence of weight gain and decreased meal‐induced symptoms in spite of a suppressed meal‐induced IGP drop, point towards a central mode of action. Mirtazapine does not display changes in gastric sensorimotor function that could explain its beneficial effects on symptoms and nutrient tolerance in FD .